News at a Glance
 Nov 22, 2011 - Shire Announces Regulatory Filings in US and EU for New Manufacturing Facility
Oct 24, 2011 - Sanofi Appoints David Meeker Chief Executive Officer of Genzyme
Sep 08, 2011 - Protalix BioTherapeutics' Taliglucerase Alfa Phase III Results Published in Blood, the Journal of the American Society of Hematology
Aug 17, 2011 - Protalix BioTherapeutics Announces FDA Accepts for Review Complete Response Resubmission for Taliglucerase Alfa and Assigns PDUFA date
Aug 01, 2011 - Protalix Submits Reply to FDA Complete Response Letter for Taliglucerase Alfa and Reports Top-Line Results from the Company's Switchover Trial
Jul 05, 2011 - Genzyme Launches the Cerezyme® Co-pay Assistance Program
Jun 20, 2011 - Shire Launches First BRAVE Awards to Recognise Carers
Jun 16, 2011 - Genzyme Celebrates 20th Anniversary of Gaucher Disease Registry with Launch of New Web Platform
Feb 25, 2011 - FDA Issues Complete Response Letter for Taliglucerase Alfa New Drug Application
Feb 18, 2011 - Three-Year Data from Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Sustained or Further Improvement Across All Endpoints
Feb 16, 2011 - Sanofi-Aventis to acquire Genzyme
Jan 31, 2011 - Genzyme and Sanofi agree on deal outline: sources
Jan 19, 2011 - Orally-delivered glucocerebrosidase enzyme (GCD) for the treatment of Gaucher Disease
Aug 26, 2010 - Shire Announces European Approval of VPRIV® for the Treatment of Type 1 Gaucher Disease
Jul 21, 2010 - Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) Supply Outlook
Jul 12, 2010 - Protalix BioTherapeutics Receives PDUFA Date for taliglucerase alfa
Jul 1, 2010 - Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV® (Velaglucerase Alfa) Through 69 Months
Jun 29, 2010 - Cerezyme® (imiglucerase for injection) Supply Update
Apr 27, 2010 - Protalix Submits Validation Data on Manufacturing Process to FDA
Apr 21, 2010 - Genzyme Provides Update on Product Supply and Consent Decree Terms
Mar 24, 2010 - Genzyme Announces FDA Enforcement Action Regarding Allston Plant
Feb 26, 2010 - Shire Announces FDA Approval of VPRIVTTM (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
Feb 17, 2010 - Genzyme Reports Financial Results for Fourth Quarter of 2009 and Full Year
Feb 11, 2010 - Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Continued Improvement Across All Endpoints
Feb 11, 2010 - Protalix Presents Additional Phase III Data for taliglucerase alfa at the WORLD Symposium
Feb 2, 2010 - Protalix Announces NDA Submission Update for taliglucerase alfa for the Treatment of Gaucher Disease
|
